Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Cancer Res. 2020 Jan 28;80(7):1551–1563. doi: 10.1158/0008-5472.CAN-19-3183

Figure 6.

Figure 6.

Pseudotime analysis and organoid testing of lung tumors. For patients’ clinicopathological information, see Supplementary Table S1. A, Diffusion maps of linear model. B, Diffusion maps of punctuated model. C, Diffusion maps of punctuated regression model. D, Flow chart of a short-term drug treatment process in patient-derived organoids (PDOs). E, Bright view images of organoid morphology (Scale bar = 500 μm). F, Examples of Immunofluorescence images of DAPI (blue), CD45 (red), pan-cytokeratin (green), and EpCAM (purple) in PDOs (Scale bar = 40 μm). G, Bar graph of cell viability at 72 hr in 20 nmol/L TP-0903 and/or 15 μmol/L ruxolitinib treated PDOs (Duncan multiple range test; *, P < 0.05; **, P < 0.01; ***, P < 0.001). Doses were selected based on in vitro testing of lung cancer cell lines (see Fig. 2D).